STAT3 and diffuse large B-cell lymphoma: These findings indicate that STAT3 inhibition is essential for regulating therapy, and combining antiretroviral therapy with autophagy inducers or STAT3 inhibitors could offer a novel treatment strategy for DLBCL [325].